Compare Moderna, Inc. (MRNA) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Standard Lithium Ltd — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Standard Lithium Ltd trades at $1.58 (market cap $398.07M). The key difference: Moderna, Inc. is far larger — about 197.6× Standard Lithium Ltd's market cap, and Moderna, Inc. is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Standard Lithium Ltd for 23 Days on average.
| MRNA | SLI | |
|---|---|---|
Market Cap | $78.65B | $398.07M |
Volume | 37,373,437 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $203.46 | $5.65 |
52-Week Low | $22.36 | $1.61 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $74.80B | $260.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Standard Lithium (SLI) trades at $1.58, down 4.24% today, with a bearish technical signal but bullish oscillators. The company shows negative profitability metrics with ROE at -15.55% and net income of -$48.40M for 2025, though recent quarterly EPS have beaten expectations. Positive developments include progress toward a final investment decision for the South West Arkansas lithium project by end of 2026 and expanded offtake agreements.
The outlook is mixed: analyst consensus is strongly bullish with a $3.83 price target (142% upside), but execution risks remain high as the company transitions to production. Key risks include project delays, funding needs, and negative cash flow from operations. The stock offers high potential reward but requires careful risk assessment given pre-revenue status.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
